Increased comorbidity burden among HDV infection vs HBV mono-infection among commercially insured adults in the United States: An All-Payer Claims Database analysis

Increased comorbidity burden among HDV infection vs HBV mono-infection among commercially insured adults in the United States: An All-Payer Claims Database analysis

Abstract BACKGROUND: Hepatitis delta is caused by a defective RNA virus (HDV) that requires the presence of hepatitis B surface antigen for replication and transmission. Compared to hepatitis B virus (HBV) monoinfection, patients with HDV have a greater risk of...
Increased comorbidity burden among HDV infection vs HBV mono-infection among commercially insured adults in the United States: An All-Payer Claims Database analysis

Hepatitis delta among commercially-insured patients in the United States: An analysis of prevalence, patient characteristics and socioeconomic status

Abstract BACKGROUND: Hepatitis delta virus (HDV) requires hepatitis B virus (HBV) for its replication. HDV infection leads to the most severe form of viral hepatitis, which is associated with an increased risk of liver-related morbidity and mortality. HDV prevalence...
Increased comorbidity burden among HDV infection vs HBV mono-infection among commercially insured adults in the United States: An All-Payer Claims Database analysis

Ramucirumab+docetaxel post immune checkpoint inhibitors and platinum-based chemotherapy in advanced or metastatic non-small cell lung cancer: Learnings from the TREAT-LUNG Observational Study

Abstract OBJECTIVES: Adding ramucirumab to docetaxel after failure of chemotherapy improves response rates and survival in aNSCLC. TREAT-LUNG aimed to characterize real-world use of ramucirumab+docetaxel or docetaxel, following ICIs and chemo for aNSCLC. METHODS:...
Increased comorbidity burden among HDV infection vs HBV mono-infection among commercially insured adults in the United States: An All-Payer Claims Database analysis

Evaluation of health care resource utilization and costs among bio-experienced Crohn’s disease patients treated with biologics with two years of follow-up

Abstract Objective: This study examined Crohn’s Disease (CD)-related healthcare resource utilization (HCRU) and costs among bio-experienced CD patients treated with biologics over a 2-year follow-up. Methods: This descriptive study used claims data pooled from Optum...